![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Psychiatry, Harvard Medical School and the Division of Neurochemistry, New England Primate Research Center, Southborough, Massachusetts
Received December 22, 2005; accepted April 4, 2006
| Abstract |
|---|
|
|
|---|
Axon guidance molecules are also implicated in adaptive responses to the psychostimulant drug cocaine in adult brain, because cocaine promotes significant changes in gene expression of axon guidance molecules, in a dosing regimen- and brain regionspecific manner (Yue et al., 1999
; Halladay et al., 2000
; Bahi and Dreyer, 2005
). Cocaine is an indirect agonist at dopamine and glutamate receptors, which are associated with promoting cocaine-induced behavioral effects and intracellular neuroadaptive cascades (Wolf et al., 2003
; Kalivas, 2004
). Whereas these intriguing findings establish a potential causality between drug-induced receptor activity and changes in gene expression of axon guidance molecules, no direct evidence links changes in receptor activity or signaling with modulation of gene expression of axon guidance molecules. We postulate that activation of GPCRs or augmentation of cAMP levels could alter gene expression of axon guidance molecules. To decipher this potential link, we investigated whether forskolin-mediated elevation of cAMP or activation of GPCRs by monoamine receptor agonists (dihydrexidine or SKF81297) changes expression of genes encoding axon guidance molecules. Our results support the underlying hypothesis that modulation of receptor activity or cAMP levels promotes adaptive responses in gene expression of axon guidance molecules. It is conceivable that our novel findings offer a molecular mechanism by which neurotransmitter or drug-receptor interaction may contribute to neuroadaptation relevant to synaptic strength, neuronal morphology, and neural networks.
| Materials and Methods |
|---|
|
|
|---|
Axon Guidance Molecule Analysis: Real-Time Reverse Transcription-PCR and Western Blot. Real time PCR was carried out using a Roche Light Cycler 2.0 system (Roche Diagnostics, Indianapolis, IN). Synthesized cDNA was diluted to 20 ng/µl and used at 50 ng per reaction. The Taqman Master kit in combination with the Universal Probe Library (Human) was used to assess gene expression (generously supplied by Roche Diagnostics, Indianapolis, IN and Penzberg, Germany). PCR primers for Taqman/Probe Library assays were designed with the Probe Library Assay Design Center (http://www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp). Two reference genes were used to normalize cDNA across samples:
-actin (NM_001101
[GenBank]
) and hydroxymethylbilane synthase (HMBS; NM_000190
[GenBank]
). Analysis of real-time PCR data was done using the 
Ct method:
Ct = Cttarget gene CtHOUSEKEEPING GENE gene, 
Ct =
Cttreated
Ctvehicle, where the change in gene expression as a result of drug treatment is given by: 2
Ct (2 is the assumed efficiency). Without an efficiency correction, the 
Ct method gives an estimated quantification of changes in gene expression. However, the use of two distinct housekeeping genes and extensive replication of experiments provides greater validity to the 
Ct method.
Immunoprecipitation followed by Western blot analysis was carried out for DCC according to standard procedures. We probed for changes in DCC protein expression in SK-N-MC cell lysate or positive control lysate (Santa Cruz Biotechnology, Santa Cruz, CA). The mouse anti-human DCC antibody, G97-449, (BD Biosciences, San Jose, CA) was used for immunoprecipitation and Western blot analysis was performed using a rabbit anti-human DCC antibody from Santa Cruz Biotechnology.
D1 Dopamine Receptor Profiling: Saturation and Competition Binding. SK-N-MC cells were washed once with ice-cold phosphate-buffered saline then lysed in 10 mM HEPES, pH 7.4 at 4°C for 15 min. SK-N-MC lysate was homogenized at 15x and spun at 28,000g then resuspended via homogenization in storage buffer (20 mM HEPES and 250 mM sucrose, pH 7.4). Membrane aliquots were snap-frozen and stored at 80°C until used. The D1 dopamine receptor density (Bmax) endogenously expressed in SK-N-MC cells was determined with [3H]SCH23390 in saturation experiments. SK-N-MC cell membranes were incubated with eight concentrations of [3H]SCH23390 (Amersham Biosciences, Piscataway, NJ) in binding buffer (50 mM HEPES and 4 mM MgCl2, pH adjusted to 7.4 with KOH). Nonspecific binding was determined using 1 µM SCH39166. Protein concentrations were determined using the Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA). Competition binding experiments were consistent with previously reported binding data for the D1 dopamine receptor. The SK-N-MC cell membranes were incubated with a single concentration of [3H]SCH23390 (12 nM) and eight concentrations of the competing test ligand in buffer (50 mM HEPES, 4 mM MgCl2, 0.01% ascorbic acid, pH adjusted to 7.4 with KOH). The Ki value for each test compound was determined using a Cheng-Prusoff equation (Cheng and Prusoff, 1973
).
cAMP Accumulation. cAMP accumulation assays were carried out using the same procedure for drug treatment of SK-N-MC cells in a six-well plate (as described above) with a 30-min drug incubation. The assay was stopped with lysis buffer (250 µl) supplied with the HitHunter cAMP XS Kit (DiscoveRx, Fremont, CA), and a 2-µl lysate aliquot was added in triplicate to a 96-well plate to determine intracellular cAMP in response to 10 µM forskolin, 10 µM dihydrexidine, 10 µM forskolin plus 10 µM dihydrexidine, 50 µM SCH23390 (Sigma-Aldrich) plus 10 µM dihydrexidine, or 50 µM SCH23390 alone.
| Results |
|---|
|
|
|---|
Using cocaine-induced gene expression changes in rodent brain as a guide (Bahi and Dreyer, 2005
), we then determined whether the SK-N-MC human neuroepithelioma cell line expressed 26 axon guidance molecules of interest. We found that 17 of the 26 axon guidance molecule target genes were expressed in this cell line (Table 1, Fig. 1). We focused on 13 of the 17 expressed axon guidance molecules that were consistent and of high yield for further assay and analysis.
|
|
Forskolin and Dihydrexidine Elevate cAMP in SK-N-MC Cells. Based on our postulate that changes in cAMP or GPCR receptor activity could alter axon guidance molecule expression, we first determined the feasibility of increasing cAMP levels by forskolin or by activation of endogenous dopamine receptors. SK-N-MC cells treated for 30 min with 10 µM forskolin increased cAMP approximately 340% above vehicle. The D1 dopamine receptor agonist dihydrexidine (10 µM dihydrexidine, 30 min) resulted in much lower stimulation of cAMP, 22% above vehicle controls, which was reduced to 10% after pretreatment with the D1 dopamine receptor antagonist SCH23390 for 20 min. Longer incubation periods did not further enhance cAMP production over vehicle. Therefore, dihydrexidine-induced cAMP increase was partially mediated by D1 receptors or the antagonist concentration was insufficient to fully attenuate cAMP activation. The combined effects of dihydrexidine and forskolin were potentiated and not additive, in that cAMP accumulation increased to
507% over vehicle (Fig. 2).
|
-actin and HMBS. Forskolin increased EphA5, EphB2, and Neuropilin1 (NRP1) expression. Cells exposed to dihydrexidine, a dopamine receptor agonist (Fig. 3B), responded to dihydrexidine (10 µM, 6 h) with up-regulation of EphrinA1 and down-regulation of EphrinA5, the ephrin receptor, EphB1, the netrin receptor, DCC, and Semaphorin3C. To confirm that changes in protein expression paralleled changes in gene expression, we performed Western blot analysis of DCC protein as described under Materials and Methods. Dihydrexidine treatment decreased DCC protein levels in agreement with changes in DCC gene expression (Fig. 3C). To extend these findings to another D1 dopamine receptor agonist, we conducted parallel studies with SKF81927, using data from three of four experiments. SFK81297 promoted an increase in EphA5, EphrinA1, EphrinA5, and NRP1 genes, paralleling forskolin-mediated increases in expression of EphA5 and NRP1 genes and dihydrexidine increases in Ephrin A1 (Fig. 4). SKF also reduced expression of EphrinB3.
|
|
We attempted to block dopamine receptor agonist-mediated effects with dopamine receptor antagonists, but the D1-like receptor antagonist SCH23390 alone (50 µM,6h; n = 8) regulated the two housekeeping genes and another D1 dopamine receptor antagonist SCH39166 (10 µM, n = 3) altered expression patterns of axon guidance molecules. Treatment of SK-N-MC cells with the D2 receptor antagonist eticlopride (50 µM, 6 h; n = 4) had no effect on the gene changes mediated by 10 µM dihydrexidine but increased the magnitude of the EphrinA1 increase mediated by dihydrexidine (data not shown).
| Discussion |
|---|
|
|
|---|
cAMP and GPCR Stimulation: Association with Axon Guidance Molecule Expression. Cells exposed to forskolin consistently increased expression of EphA5, EphB2, and NRP1. The discrete biochemical sequelae mediating gene induction are unknown; conceivably, however, a surge of cAMP production can trigger transcriptional activity to augment expression of EphA5 and EphB2 receptor genes. EphA5 and EphB2 are implicated in synaptic plasticity and synaptogenesis in the adult rodent hippocampus (Gao et al., 1998
; Martinez et al., 2005
). EphA5 may also contribute to drug-induced modulation of long-term potentiation in the CA1 region and decreased neurogenesis in adult rat hippocampus (Thompson et al., 2005
; Yamaguchi et al., 2005
). EphB2 receptors subserve a different spectrum of functions by modulating LTP, NMDA receptor function, and normal spine formation in the hippocampus (Grunwald et al., 2001
; Henderson et al., 2001
). The semaphorin receptor neuropilin1 binds semaphorin class 3 molecules, but neuropilin1 function in adult brain is poorly understood. Notwithstanding the caveats associated with a cell culture model system, cAMP regulation of axon guidance molecules in the SK-N-MC cell line may be relevant to cAMP modulation of axon guidance molecules in neurons.
In contrast to forskolin, dihydrexidine up- or down-regulated a different and larger repertoire of axon guidance molecules. The agonist-induced changes in gene expression were not fully blocked by D1 or D2 receptor antagonists, in that the D1 dopamine receptor antagonists SCH23390 and SCH39166 had direct effects either on housekeeping genes or on axon guidance molecule expression, respectively. It is possible that endogenous receptors with constitutive activity, by themselves, can modulate axon guidance molecules, with implications for therapeutic receptor antagonist drugs. Despite the comparatively modest dihydrexidine-induced increase in cAMP, changes elicited by dihydrexidine were of higher magnitude than those of forskolin. Dihydrexidine induced up-regulation of EphrinA1, a ligand implicated in neurogenesis of neural stem cells via Rap1 and the MAPK pathway (Aoki et al., 2004
) and associated with delineating the striatal matrix (Janis et al., 1999
). Whether it functions in adult brain or contributes to enhanced striosome predominance of early gene expression in brain of monkeys treated repeatedly with cocaine remains unknown (Saka et al., 2004
).
The dihydrexidine-mediated decrease in EphB1 gene expression in cell culture paralleled EphB1 down-regulation in the nucleus accumbens shell of rats self-administering cocaine (Kumaresan et al., 2005
). Dihydrexidine also reduced the gene encoding the netrin receptor DCC, required for both repulsive and attractive responses to netrin1 (Hong et al., 1999
). In adult rodent brain, DCC protein is expressed in dopaminergic neurons and their terminal fields (Osborne et al., 2005
).
Why Do Forskolin and Dihydrexidine Modulate Axon Guidance Molecules Differently? GPCR activation or cAMP production was associated with axon guidance molecule modulation but not via a simple stoichiometric relationship. Nonparallel changes in gene expression of axon guidance molecules elicited by forskolin or receptor agonists were anticipated, in view of the significant differences in forskolin- and D1 receptor-mediated signaling events. Forskolin-stimulated cAMP production was >10-fold higher than dihydrexidine, possibly triggering a different cascade of concentration-dependent signaling actions. Furthermore, at 10 µM, dihydrexidine is likely to activate both D1 and D2 dopamine receptors, and possibly
2 adrenergic receptors, which are expressed in SK-N-MC cells (Schaak et al., 1997
). It is noteworthy that dihydrexidine potentiated forskolin induction of cAMP, indicating that dihydrexidine did not stimulate Gi/Go-coupled GPCRs. Furthermore, the D1 dopamine receptor mediates signaling cascades in addition to cAMP and can heterodimerize with other receptors (Gines et al., 2000
; O'Dowd et al., 2005
). Levels of gene expression of axon guidance molecules engendered by SKF81297 overlapped with, but were not identical to changes elicited by forskolin or dihydrexidine. This finding was also anticipated because, at the concentrations we used, SKF81297 would conceivably activate a range of receptors (including 5-HT2C, 5-HT2A, and
2-adrenergic receptors) if expressed in this cell line (NIMH Psychoactive Drug Screening Program; http://pdsp.cwru.edu/pdsp.htm). Drug-induced modulation of axon guidance molecule expression is likely to reflect an array of signal transduction sequelae triggered by activating various GPCR receptors, as a function of agonist concentration.
Axon Guidance Molecules and Neuroadaptation. In cultured neuroepithelioma cells, exogenous compounds increased cAMP levels, and enhanced cAMP levels were associated with altered axon guidance molecule gene and protein expression. We recognize the perils of extrapolating observations and mechanisms based on cultured cells to organized brain tissue, because cultured cells do not model complex neuronal interactions, time course, and neuron-specific responses. Notwithstanding these caveats, the relevance of our findings to drug-induced modulation of axon guidance molecules in brain merit exploration. Axon guidance molecules are expressed in adult human and nonhuman primate brain (Hafner et al., 2004
; Xiao et al., 2006
) and are increasingly implicated in synaptic function and neuroadaptation (Yamaguchi and Pasquale, 2004
; Pasquale, 2005
) as well as response to the psychomotor stimulant cocaine. Various dosing regimens of cocaine modulate axon guidance molecules in a region-specific manner (Bahi and Dreyer, 2005
), suggestive of causality between psychostimulant-induced receptor activation, axon guidance molecule changes, and neuroadaptation. The mechanisms by which cocaine might modulate axon guidance molecules are unknown, but cocaine-induced neurotransmitter activation of the Gs-coupled D1 dopamine receptors (or other receptors) and consequent elevation of cAMP may be linked to axon guidance molecule modulation (Yue et al., 1999
; Halladay et al., 2000
; Bahi and Dreyer, 2005
; Xiao et al., 2006
). Cocaine-mediated neuroadaptation extends beyond the cellular level, to changes in synaptic strength, neuronal morphology and neural networks (Dong et al., 2004
; Robinson and Kolb, 2004
; Saka et al., 2004
), processes that conceivably involve axon guidance molecule function. It is noteworthy that several axon guidance molecule genes altered by forskolin or dihydrexidine, were regulated in the same direction by cocaine administration in rat brain (Bahi and Dreyer, 2005
). Enhanced cAMP levels, via axon guidance molecule transcriptional regulation may also contribute to hippocampal plasticity. Axon guidance molecules in hippocampus are implicated in modulating LTP and NMDA receptor function (Henderson et al., 2001
; Contractor et al., 2002
). Of relevance to the present study is that forskolin is frequently used to induce LTP (Otmakhov et al., 2004
), via enhanced cAMP that modulates gene expression of axon guidance molecules. Although highly speculative, axon guidance molecules may also contribute to antidepressant drug-induced hippocampal neurogenesis by guiding integration of newly formed neurons (Santarelli et al., 2003
).
It is conceivable that exogenous compounds that activate neuron-specific membrane receptors and ion channels converge to trigger unique intracellular signaling cascades that govern the repertoire of axon guidance molecules. In this way, gene expression of axon guidance molecules may modulate neuronal activity and connectivity at many levels to provide a rich array of rapid or gradual neuroadaptive responses. The bidirectional signaling of membrane-associated axon guidance molecules renders them well suited to mediate anterograde and retrograde directed information at synapses. This study provides an initial view and potential link between cAMP modulation by physiological or pharmacological compounds and changes in axon guidance molecules. The novel underlying hypothesis and implications of this work may be relevant not only to neuroadaptive responses elicited by addictive and therapeutic drugs (e.g., cocaine, antipsychotics, antidepressants) but also to other receptor-mediated mechanisms in neurons, such as learning and memory.
| Acknowledgements |
|---|
| Footnotes |
|---|
This research was previously presented in abstract form at the annual meeting of the Society for Neuroscience: Jassen AK, Yang H, Miller GM, and Madras BK (2005) Axonal guidance molecule gene expression is regulated by cAMP stimulants: implications for drug-induced neuroadaptation in brain. Soc Neurosci Abstr 31:1032.14.
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
ABBREVIATIONS: GPCR, G-protein-coupled receptor; SKF81297, (±)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide; SCH23390, R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; SCH 39166, ()-trans-6,7,7
, 8,9,13
-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo[d]naphtho[2,1-b]azepine; PCR, polymerase chain reaction; HMBS, hydroxymethylbilane synthase; DCC, deleted in colorectal cancer; NRP1, neuropilin1; Ct, crossing threshold; LTP, long-term potentiation.
Address correspondence to: Bertha K. Madras, Department of Psychiatry, Harvard Medical School, Division of Neurochemistry, New England Regional Primate Research Center, 1 Pine Hill Drive, Southborough, MA 01772-9102. E-mail: bertha_madras{at}hms.harvard.edu
| References |
|---|
|
|
|---|
Bahi A and Dreyer JL (2005) Cocaine-induced expression changes of axon guidance molecules in the adult rat brain. Mol Cell Neurosci 28: 275291.[CrossRef][Medline]
Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 30993108.[CrossRef][Medline]
Contractor A, Rogers C, Maron C, Henkemeyer M, Swanson GT, and Heinemann SF (2002) Trans-synaptic Eph receptor-ephrin signaling in hippocampal mossy fiber LTP. Science (Wash DC) 296: 18641869.
Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW, and Greenberg ME (2000) EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 103: 945956.[CrossRef][Medline]
Dong Y, Saal D, Thomas M, Faust R, Bonci A, Robinson T, and Malenka RC (2004) Cocaine-induced potentiation of synaptic strength in dopamine neurons: behavioral correlates in GluRA(/) mice. Proc Natl Acad Sci USA 101: 1428214287.
Gao WQ, Shinsky N, Armanini MP, Moran P, Zheng JL, Mendoza-Ramirez JL, Phillips HS, Winslow JW, and Caras IW (1998) Regulation of hippocampal synaptic plasticity by the tyrosine kinase receptor, REK7/EphA5, and its ligand, AL-1/Ephrin-A5. Mol Cell Neurosci 11: 247259.[CrossRef][Medline]
Gerlai R (2001) Eph receptors and neural plasticity. Nat Rev Neurosci 2: 205209.[CrossRef][Medline]
Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, Rondin S, Lew JY, Watson S, Zoli M, et al. (2000) Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97: 86068611.
Grunwald IC, Korte M, Wolfer D, Wilkinson GA, Unsicker K, Lipp HP, Bonhoeffer T, and Klein R (2001) Kinase-independent requirement of EphB2 receptors in hippocampal synaptic plasticity. Neuron 32: 10271040.[CrossRef][Medline]
Grunwald IC, Korte M, Adelmann G, Plueck A, Kullander K, Adams RH, Frotscher M, Bonhoeffer T, and Klein R (2004) Hippocampal plasticity requires postsynaptic ephrinBs. Nat Neurosci 7: 3340.[CrossRef][Medline]
Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, and Vogt T (2004) Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50: 490499.
Halladay AK, Yue Y, Michna L, Widmer DA, Wagner GC, and Zhou R (2000) Regulation of EphB1 expression by dopamine signaling. Brain Res Mol Brain Res 85: 171178.[Medline]
Henderson JT, Georgiou J, Jia Z, Robertson J, Elowe S, Roder JC, and Pawson T (2001) The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Neuron 32: 10411056.[CrossRef][Medline]
Hong K, Hinck L, Nishiyama M, Poo MM, Tessier-Lavigne M, and Stein E (1999) A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. Cell 97: 927941.[CrossRef][Medline]
Janis LS, Cassidy RM, and Kromer LF (1999) Ephrin-A binding and EphA receptor expression delineate the matrix compartment of the striatum. J Neurosci 19: 49624971.
Kalivas PW (2004) Glutamate systems in cocaine addiction. Curr Opin Pharmacol 4: 2329.[CrossRef][Medline]
Klein R (2001) Excitatory Eph receptors and adhesive ephrin ligands. Curr Opin Cell Biol 13: 196203.[CrossRef][Medline]
Knoll B and Drescher U (2002) Ephrin-As as receptors in topographic projections. Trends Neurosci 25: 145149.[CrossRef][Medline]
Kumaresan V, Schmidt HD, and Pierce RC (2005) Effects of cocaine self-administration on the expression of ephrins and their receptors in the core and shell of the nucleus accumbens. Soc Neurosci Abstr 31: 561.21
Lohof AM, Quillan M, Dan Y, and Poo MM (1992) Asymmetric modulation of cytosolic cAMP activity induces growth cone turning. J Neurosci 12: 12531261.[Abstract]
Martinez A, Otal R, Sieber BA, Ibanez C, and Soriano E (2005) Disruption of ephrin-A/EphA binding alters synaptogenesis and neural connectivity in the hippocampus. Neuroscience 135: 451461.[CrossRef][Medline]
Murai KK, Nguyen LN, Irie F, Yamaguchi Y, and Pasquale EB (2003) Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. Nat Neurosci 6: 153160.[CrossRef][Medline]
O'Dowd BF, Ji X, Alijaniaram M, Rajaram RD, Kong MM, Rashid A, Nguyen T, and George SR (2005) Dopamine receptor oligomerization visualized in living cells. J Biol Chem 280: 3722537235.
Osborne PB, Halliday GM, Cooper HM, and Keast JR (2005) Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience 131: 671681.[CrossRef][Medline]
Otmakhov N, Khibnik L, Otmakhova N, Carpenter S, Riahi S, Asrican B, and Lisman J (2004) Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent. J Neurophysiol 91: 19551962.
Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6: 462475.[CrossRef][Medline]
Penzes P, Beeser A, Chernoff J, Schiller MR, Eipper BA, Mains RE, and Huganir RL (2003) Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rho-GEF kalirin. Neuron 37: 263274.[CrossRef][Medline]
Robinson TE and Kolb B (2004) Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 47 (Suppl 1): 3346.
Saka E, Goodrich C, Harlan P, Madras BK, and Graybiel AM (2004) Repetitive behaviors in monkeys are linked to specific striatal activation patterns. J Neurosci 24: 75577565.
Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (Wash DC) 301: 805809.
Schaak S, Cayla C, Blaise R, Quinchon F, and Paris H (1997) HepG2 and SK-N-MC: two human models to study
2 adrenergic receptors of the alpha-2C subtype. J Pharmacol Exp Ther 281: 983991.
Sidhu A and Fishman PH (1990) Identification and characterization of functional D1 dopamine receptors in a human neuroblastoma cell line. Biochem Biophys Res Commun 166: 574579.[CrossRef][Medline]
Song HJ, Ming GL, and Poo MM (1997) cAMP-induced switching in turning direction of nerve growth cones. Nature (Lond) 388: 275279.[CrossRef][Medline]
Song HJ and Poo MM (1999) Signal transduction underlying growth cone guidance by diffusible factors. Curr Opin Neurobiol 9: 355363.[CrossRef][Medline]
Thompson AM, Swant J, and Wagner JJ (2005) Cocaine-induced modulation of long-term potentiation in the CA1 region of rat hippocampus. Neuropharmacology 49: 185194.[CrossRef][Medline]
Wolf ME, Mangiavacchi S, and Sun X (2003) Mechanisms by which dopamine receptors may influence synaptic plasticity. Ann NY Acad Sci 1003: 241249.
Xiao D, Miller GM, Jassen A, Westmoreland SV, Pauley D, and Madras BK (2006 Jan 5) Ephrin/Eph receptor expression in brain of adult nonhuman primates: implications for neuroadaptation. Brain Res 1067: 6777.[CrossRef][Medline]
Yamaguchi M, Suzuki T, Seki T, Namba T, Liu J, Arai H, Hori T, and Shiga T (2005) Decreased cell proliferation in the dentate gyrus of rats after repeated administration of cocaine. Synapse 58: 6371.[CrossRef][Medline]
Yamaguchi Y and Pasquale EB (2004) Eph receptors in the adult brain. Curr Opin Neurobiol 14: 288296.[CrossRef][Medline]
Yue Y, Widmer DA, Halladay AK, Cerretti DP, Wagner GC, Dreyer JL, and Zhou R (1999) Specification of distinct dopaminergic neural pathways: roles of the Eph family receptor EphB1 and ligand ephrin-B2. J Neurosci 19: 20902101.
Zhou R (1998) The Eph family receptors and ligands. Pharmacol Ther 77: 151181.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
Y. Iwakura, H. Nawa, I. Sora, and M. V. Chao Dopamine D1 Receptor-induced Signaling through TrkB Receptors in Striatal Neurons J. Biol. Chem., June 6, 2008; 283(23): 15799 - 15806. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, A. Vinuela, M. H. Neely, P. J. Hallett, S. G. N. Grant, G. M. Miller, O. Isacson, M. G. Caron, and W.-D. Yao Inhibition of the Dopamine D1 Receptor Signaling by PSD-95 J. Biol. Chem., May 25, 2007; 282(21): 15778 - 15789. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xie, S. V. Westmoreland, M. E. Bahn, G.-L. Chen, H. Yang, E. J. Vallender, W.-D. Yao, B. K. Madras, and G. M. Miller Rhesus Monkey Trace Amine-Associated Receptor 1 Signaling: Enhancement by Monoamine Transporters and Attenuation by the D2 Autoreceptor in Vitro J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 116 - 127. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||